156 related articles for article (PubMed ID: 22475985)
21. A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pain modulation: a human experimental study.
Arendt-Nielsen L; Andresen T; Malver LP; Oksche A; Mansikka H; Drewes AM
Clin J Pain; 2012 Sep; 28(7):623-7. PubMed ID: 22156892
[TBL] [Abstract][Full Text] [Related]
22. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
23. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
Strain EC; Walsh SL; Bigelow GE
Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
[TBL] [Abstract][Full Text] [Related]
24. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine.
Koltzenburg M; Pokorny R; Gasser UE; Richarz U
Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645
[TBL] [Abstract][Full Text] [Related]
25. Buprenorphine for chronic pain.
Calderon R; Copenhaver D
J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
[TBL] [Abstract][Full Text] [Related]
26. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
27. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
28. Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs.
Nordbø A; Skurtveit S; Borchgrevink PC; Kaasa S; Fredheim OM
Acta Anaesthesiol Scand; 2012 Jan; 56(1):88-94. PubMed ID: 22092357
[TBL] [Abstract][Full Text] [Related]
29. Combination oxycodone 5 mg/ibuprofen 400 mg for the treatment of pain after abdominal or pelvic surgery in women: a randomized, double-blind, placebo- and active-controlled parallel-group study.
Singla N; Pong A; Newman K;
Clin Ther; 2005 Jan; 27(1):45-57. PubMed ID: 15763605
[TBL] [Abstract][Full Text] [Related]
30. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
31. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
33. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
34. No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery.
Okkerse P; Alvarez-Jimenez R; Hay JL; Tehim A; Kumar R; de Kam ML; Groeneveld GJ
Eur J Pain; 2017 Mar; 21(3):494-506. PubMed ID: 27651026
[TBL] [Abstract][Full Text] [Related]
35. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain.
James IG; O'Brien CM; McDonald CJ
J Pain Symptom Manage; 2010 Aug; 40(2):266-78. PubMed ID: 20541900
[TBL] [Abstract][Full Text] [Related]
37. Anti-hyperalgesia properties of buprenorphine.
Russo MA
Pain; 2006 May; 122(1-2):216; author reply 216. PubMed ID: 16524662
[No Abstract] [Full Text] [Related]
38. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients?
Skurtveit S; Furu K; Kaasa S; Borchgrevink PC
Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
40. A single-tablet fixed-dose combination of racemic ibuprofen/paracetamol in the management of moderate to severe postoperative dental pain in adult and adolescent patients: a multicenter, two-stage, randomized, double-blind, parallel-group, placebo-controlled, factorial study.
Mehlisch DR; Aspley S; Daniels SE; Southerden KA; Christensen KS
Clin Ther; 2010 Jun; 32(6):1033-49. PubMed ID: 20637958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
